Results from the primary analysis of a 30 patient extension...

European Journal of Cancer 2020 / 10 Vol. 138

Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

Macchini, M., Garralda, E., Fiedler, W., Del Conte, G., Rolling, C., Kebenko, M., Klinghammer, K.F., Ahrens-fath, I., Habel, B., Baumeister, H., Zurlo, A., Ochsenreiter, S.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
138
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(20)31083-2
Date:
October, 2020
File:
PDF, 714 KB
2020
Conversion to is in progress
Conversion to is failed